drug

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

Study now open for enrollment at leading academic medical centersCARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity…

1 week ago

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support…

2 weeks ago

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress…

3 weeks ago

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances…

3 weeks ago

Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with…

4 weeks ago

LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions

ANDERNACH, Germany, April 29, 2026 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced…

1 month ago

ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406

SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy…

2 months ago

API Innovation Center Highlights Fragility in U.S. Drug Supply Chain in New White Paper

ST. LOUIS, March 10, 2026 (GLOBE NEWSWIRE) -- The API Innovation Center (APIIC), a nonprofit dedicated to strengthening national health security…

3 months ago

U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If…

3 months ago

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board

HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in…

3 months ago